ATI RN
ATI Pharmacology Proctored
1. Which of the following conditions is not treated with Nifedipine?
- A. Angina
- B. Arrhythmias
- C. Hypertension
- D. Fluid retention
Correct answer: D
Rationale: Nifedipine is a calcium channel blocker primarily used in the management of angina and hypertension. It is not typically used to treat arrhythmias or fluid retention. Angina is chest pain caused by reduced blood flow to the heart, and hypertension is high blood pressure. Therefore, fluid retention is the condition that is not treated with Nifedipine.
2. A client has a new prescription for Raltegravir. Which of the following statements should the nurse include in teaching the client?
- A. This medication prevents the virus from entering the cell.
- B. This medication prevents the virus from leaving the cell.
- C. This medication blocks the virus from attaching to the cell.
- D. This medication blocks the virus from replicating in the cell.
Correct answer: D
Rationale: The correct answer is D because Raltegravir works by blocking the integrase enzyme, preventing the virus from integrating its genetic material into the host cell's DNA. By inhibiting this process, viral replication within the host cell is halted. Choices A, B, and C are incorrect because Raltegravir's mechanism of action specifically targets viral replication within the cell, not virus entry, exit, or attachment to the cell.
3. A client with cancer is prescribed methotrexate. Which supplement should the healthcare provider recommend to reduce the risk of methotrexate toxicity?
- A. Folic acid
- B. Magnesium
- C. Vitamin D
- D. Iron
Correct answer: A
Rationale: The correct answer is folic acid. Methotrexate is a folic acid antagonist, and supplementing with folic acid can help reduce the risk of methotrexate toxicity. Folic acid supplementation is commonly recommended to counteract the effects of methotrexate on folate metabolism. Magnesium, Vitamin D, and Iron are not specifically indicated to reduce the risk of methotrexate toxicity and therefore are incorrect choices in this scenario.
4. A client has a new prescription for nitroglycerin transdermal patches. Which of the following instructions should the nurse include?
- A. Apply the patch to a different location each day.
- B. Remove the patch every night before bedtime.
- C. Massage the patch area gently after application.
- D. Shave the area before applying the patch.
Correct answer: B
Rationale: The correct instruction for a client using nitroglycerin transdermal patches is to remove the patch every night before bedtime. This practice helps prevent tolerance to the medication's effects. Continuous exposure to nitroglycerin can result in the body becoming less responsive to its therapeutic effects over time, reducing its efficacy in managing the prescribed condition. Choices A, C, and D are incorrect. Applying the patch to a different location each day does not address the issue of tolerance. Massaging the patch area gently after application is not recommended as it may alter drug absorption. Shaving the area before applying the patch is unnecessary and may increase the risk of skin irritation.
5. When using Nitroglycerine (transdermal), how many hours should you be nitrate-free each day?
- A. 1-2 hours
- B. 5-10 hours
- C. 3-4 hours
- D. 10-12 hours
Correct answer: D
Rationale: When using Nitroglycerine (transdermal), it should be applied for 10-12 hours per day to ensure its effectiveness. A nitrate-free period within the day is essential to prevent the development of tolerance to the medication.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access